This study examines the safety and efficacy of a gene therapy involving the follistatin and klotho genes. It enrolls generally healthy adults between 50 and 80 years of age. The study is in Early Phase 1 and is currently recruiting participants.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Adults aged 50 to 80 years * General good health * Willing to comply with all study-related procedures and visits * Participant is open to morphological change * If female, participant agrees to maintain contraception * If female, participant agrees to take a pregnancy test * If female, participant agrees to a pregnancy waiver Exclusion Criteria: * Currently enrolled in another clinical trial * History of cancer, autoimmune disease, or chronic kidney/liver disease * Use of immunosuppressive therapy * Pregnant or breastfeeding * Women of childbearing potential who are unwilling or unable to use effective contraception for the duration of the study. * Regular use of NMDA (N-methyl-D-aspartate) antagonists (i.e., memantine, ketamine, etc.) * Regular use of antiplatelet medications (i.e., aspirin) * Any medical or psychiatric condition that could interfere with participation or pose safety concerns * Unwilling or unable to provide informed consent